{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:01:02Z","timestamp":1777698062325,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T00:00:00Z","timestamp":1357603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s11899-012-0147-9","type":"journal-article","created":{"date-parts":[[2013,1,7]],"date-time":"2013-01-07T01:59:41Z","timestamp":1357523981000},"page":"1-6","source":"Crossref","is-referenced-by-count":83,"title":["Ibrutinib (PCI-32765), the First BTK (Bruton\u2019s Tyrosine Kinase) Inhibitor in Clinical Trials"],"prefix":"10.1007","volume":"8","author":[{"given":"Jennifer R.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,8]]},"reference":[{"issue":"10","key":"147_CR1","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1182\/blood-2009-04-214346","volume":"114","author":"P Abrisqueta","year":"2009","unstructured":"Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980\u20132008): the Hospital Clinic of Barcelona experience. Blood. 2009;114(10):2044\u201350.","journal-title":"Blood"},{"issue":"1","key":"147_CR2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","volume":"105","author":"JC Byrd","year":"2005","unstructured":"Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49\u201353.","journal-title":"Blood"},{"issue":"9747","key":"147_CR3","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"\u2022\u2022 Hallek, M., Fischer, K., Fingerle-Rowson, G., et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747): 1164\u201374. This study has established the standard of care therapy for previously untreated CLL patients.","journal-title":"Lancet"},{"issue":"18","key":"147_CR4","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","volume":"23","author":"MJ Keating","year":"2005","unstructured":"Keating MJ, O\u2019Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079\u201388.","journal-title":"J Clin Oncol"},{"key":"147_CR5","doi-asserted-by":"crossref","unstructured":"Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;1:110\u2013118.","DOI":"10.1182\/asheducation-2011.1.110"},{"key":"147_CR6","doi-asserted-by":"crossref","unstructured":"\u2022 Davids, MS and Brown JR: Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk Lymphoma. 2012;53(12):2362\u201370. This review covers the range of inhibitors of the BCR pathway which have been studied in CLL thus far, and discusses ongoing issues with their development.","DOI":"10.3109\/10428194.2012.695781"},{"issue":"8","key":"147_CR7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1517\/14728222.2011.585971","volume":"15","author":"RW Hendriks","year":"2011","unstructured":"Hendriks RW, Bredius RG, Pike-Overzet K, Staal FJ. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opin Ther Targets. 2011;15(8):1003\u201321.","journal-title":"Expert Opin Ther Targets"},{"key":"147_CR8","doi-asserted-by":"crossref","unstructured":"Wiestner, A.: Emerging role of kinase targeted strategies in chronic lymphocytic leukemia. Blood. 2012;120(24):4684\u201391.","DOI":"10.1182\/blood-2012-05-423194"},{"issue":"29","key":"147_CR9","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"147_CR10","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SE Herman","year":"2011","unstructured":"Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287\u201396.","journal-title":"Blood"},{"issue":"11","key":"147_CR11","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MF Rooij de","year":"2012","unstructured":"de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590\u20134.","journal-title":"Blood"},{"key":"147_CR12","doi-asserted-by":"crossref","unstructured":"Ponader S, Chen SS, Buggy JJ, et al.: Bruton\u2019s tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182\u20131189.","DOI":"10.1182\/blood-2011-10-386417"},{"key":"147_CR13","doi-asserted-by":"crossref","unstructured":"Advani RH, Buggy JJ, Sharman JP, et al. The BTK Inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed\/refractory B cell malignancies: Final Results from a Phase 1 Study. J Clin Oncol. doi: 10.1200\/JCO.2012.44.4281","DOI":"10.1200\/JCO.2012.44.4281"},{"issue":"21","key":"147_CR14","first-page":"57","volume":"116","author":"JA Burger","year":"2010","unstructured":"Burger JA, O\u2019Brien S, Fowler N, et al. The Bruton\u2019s Tyrosine Kinase Inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): an update on ongoing phase 1 studies. ASH Annual Meeting Abstracts. 2010;116(21):57.","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"12","key":"147_CR15","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446\u201356.","journal-title":"Blood"},{"issue":"23","key":"147_CR16","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","volume":"30","author":"BD Cheson","year":"2012","unstructured":"\u2022 Cheson BD, Byrd JC, Rai KR, et al.: Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012, 30(23):2820\u20132. This article discusses the adaptation to the CLL response criteria which is required for the evaluation of the BCR pathway inhibitors.","journal-title":"J Clin Oncol"},{"issue":"21","key":"147_CR17","first-page":"983","volume":"118","author":"S O\u2019Brien","year":"2011","unstructured":"O\u2019Brien S, Burger J, Blum K, et al. The Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R\/R) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL): follow-up of a phase Ib\/II study. ASH Annual Meeting Abstracts. 2011;118(21):983.","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"15_suppl","key":"147_CR18","first-page":"6507","volume":"30","author":"JC Byrd","year":"2012","unstructured":"Byrd JC, Furman R, Coutre S, et al. The Bruton\u2019s tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): interim results of a phase Ib\/II study. ASCO Meeting Abstracts. 2012;30(15_suppl):6507.","journal-title":"ASCO Meeting Abstracts"},{"issue":"10","key":"147_CR19","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","volume":"28","author":"WG Wierda","year":"2010","unstructured":"Wierda WG, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749\u201355.","journal-title":"J Clin Oncol"},{"issue":"19","key":"147_CR20","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","volume":"118","author":"WG Wierda","year":"2011","unstructured":"Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011;118(19):5126\u20139.","journal-title":"Blood"},{"issue":"15_suppl","key":"147_CR21","first-page":"6508","volume":"30","author":"SM Jaglowski","year":"2012","unstructured":"Jaglowski SM, Jones J, Flynn J, et al. A phase Ib\/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases. ASCO Meeting Abstracts. 2012;30(15_suppl):6508.","journal-title":"ASCO Meeting Abstracts"},{"issue":"15_suppl","key":"147_CR22","first-page":"6515","volume":"30","author":"SM O\u2019Brien","year":"2012","unstructured":"O\u2019Brien SM, Barrientos J, Flinn I, et al. Combination of the Bruton\u2019s tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)\/rituximab (R) (BR) in patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib\/II study. ASCO Meeting Abstracts. 2012;30(15_suppl):6515.","journal-title":"ASCO Meeting Abstracts"},{"key":"147_CR23","unstructured":"Brown JR, Barrientos J, Flinn I, et al.: The Bruton\u2019s Tyrosine Kinase (BTK) inhibitor ibrutinib combined with bendamustine and rituximab is active and tolerable in patients with relapsed\/refractory CLL, interim results of a phase Ib\/II study. EHA Meeting Abstracts 2012, 97."},{"issue":"26","key":"147_CR24","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","volume":"29","author":"K Fischer","year":"2011","unstructured":"Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559\u201366.","journal-title":"J Clin Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0147-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-012-0147-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0147-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:08:17Z","timestamp":1559419697000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-012-0147-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["147"],"URL":"https:\/\/doi.org\/10.1007\/s11899-012-0147-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,8]]}}}